ClinicalTrials.gg
RecruitingNCT06096259PIKASOUpdated Oct 15, 2026

Preventing Injured Knees From osteoArthritis: Severity Outcomes

A Phase 2 interventional study of Metformin and Placebo in Osteoarthritis, Knee, Post-traumatic Osteoarthritis and ACL Tear, sponsored by Brigham and Women's Hospital. Recruiting at 9 sites in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Planned enrollment
48th of 691
512 · median 72
Started
2024
with 30 others
Phase 2
111 of 796
13 open now
Primary completion
2029-12
later than 136 of 151 live
Registered
696th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 48th largest by planned enrollment of the 691 interventional ones that give a count, is one of 31 that started in 2024, is one of 111 in phase 2, reaches primary completion later than 136 of the 151 other live ones, and was the 696th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

This study is being done to find out if metformin is effective at reducing pain by delaying the onset of post-traumatic osteoarthritis (PTOA) after anterior cruciate ligament (ACL) reconstruction. This research study will compare metformin to placebo. The placebo tablet looks exactly like metformin, but contains no metformin. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons.

Metformin is approved by the U.S. Food and Drug Administration (FDA) to treat type II diabetes. Notably, it also has anti-inflammatory effects, suggesting it could benefit people who have an ACL injury and are undergoing ACL reconstruction.

Read the detailed description

Osteoarthritis (OA) is among the most prevalent chronic, disabling conditions, occurring in over 32 million persons in the US. Worldwide, an estimated 240 million persons have symptomatic, activity-limiting OA. OA cases arising from injury are referred to as post-traumatic OA (PTOA). Approximately 12% of cases of lower extremity symptomatic OA are PTOA, often the result of injuries such as anterior cruciate ligament (ACL) rupture or ankle fracture. Four million Americans have PTOA. On average, patients with PTOA develop knee OA 10.4 years earlier than those with primary knee OA. Similarly, individuals with PTOA of the hip and ankle develop OA 9.0 and 14.0 years, respectively, earlier than their primary OA counterparts. Sustaining ACL injury early in adulthood leads to greater lifetime risk as well as earlier onset of knee OA and need for total knee replacement (TKR). The earlier age of onset means that PTOA is often a disorder of working persons, compromising productivity and quality of life. The indirect cost burden of PTOA is estimated to be \~$4.4 billion annually, because individuals are typically affected in their most productive years of employment.

Anterior cruciate ligament (ACL) injury is the most common sports-related knee injury, and many patients who wish to return to sporting activities that involve cutting and pivoting will choose to undergo ACL reconstruction (ACLR). Each year, more than 120,000 ACL reconstructions are performed in the US alone. Even though ACLR can allow people to return to sporting activities with a stable knee, there is still an increased risk of PTOA after the ACL injury and subsequent reconstruction. Studies have demonstrated that around 50% of patients who undergo ACL reconstruction develop OA within 10-15 years. Given the large number of ACL injuries and subsequent reconstructions that occur annually, and the strong association between ACL tear/reconstruction and PTOA, developing treatment strategies to delay or prevent PTOA and promote long-term health after ACLR is critical to maintaining the well-being of young, active populations. This study proposes to address these issues by testing the efficacy of metformin, a commonly used and safe drug with promising pre-clinical and clinical evidence of PTOA prevention, in younger adults undergoing ACL reconstruction.

PIKASO is a multicenter, double-blind (participants, treating clinicians, and assessors), placebo-controlled, randomized study to establish the efficacy of metformin at delaying the onset of post-traumatic osteoarthritis (PTOA) after anterior cruciate ligament reconstruction. Subjects will be randomized in a 1:1 ratio. Each subject will complete standard-of-care postoperative physical therapy in both arms. The two primary outcomes will be KOOS pain (assessed at 12 and 24 months postoperatively and averaged) and modified MRI Osteoarthritis Knee Score (MOAKS) cartilage score at 24 months postoperatively.

03

Conditions studied

  • Osteoarthritis, Knee
  • Post-traumatic Osteoarthritis
  • ACL Tear
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 25-45 or Age 18-24 with preoperative KOOS Pain \<80 (0-100, 100 best) recorded at least 14 days after the day of ACL injury
  2. Plan to undergo ACL reconstruction within 12 months of injury

Exclusion criteria

Exclusion Criteria:

  1. Inflammatory arthritis
  2. Pregnancy and/or lactation, or plans to become pregnant in the next 12 months
  3. Known to metformin
  4. Current use of metformin or topiramate
  5. Diabetes mellitus or diabetic ketoacidosis
  6. Acute or chronic renal insufficiency
  7. History of prior ACL tear on the index knee, with or without reconstruction
  8. History of ACL tear on the contralateral knee within the past 12 months
  9. Applying for or receiving Workers' Compensation for their knee injury
  10. Joint space narrowing AND definite osteophyte(s) on weightbearing radiograph on index knee
  11. Tibial plateau fracture on index knee
  12. Concomitant avulsion fracture of index knee that will be treated surgically
  13. Concomitant posterior cruciate ligament, medial collateral ligament, or lateral collateral ligament injury on index knee requiring surgical repair/reconstruction
  14. Contraindication to MRI
  15. Unable to speak and understand English
  16. Diagnosis of cognitive impairment or otherwise unable to provide
  17. Insufficient time for recruitment and drug titration: Surgery scheduled for \<14 days from the time of screening
  18. Date of injury more than 6-months ago, relative to date of screening
  19. Presence of a condition or abnormality that in the opinion of the surgeon investigator would compromise the safety of the patient or the quality of the data
  20. Plan for allograft at time of consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
512 participants (estimated)

Study arms

  • Experimental
    Metformin

    3x500mg metformin hydrochloride (HCl) extended-release (ER) tablets taken orally once a day for 1 year

    Drug: Metformin

  • Placebo comparator
    Placebo

    3x metformin placebo tablets matching metformin extended-release taken orally once a day for 1 year

    Drug: Placebo

Interventions

  • Metformin is an oral anti-hyperglycemic agent widely used as first-line treatment for type II diabetes to improve glycemic control. It is the fourth most commonly prescribed drug in the United States. Participants will receive commercially available extended-release metformin 500mg tablets manufactured by Granules India Limited, Hyderabad, India and then sourced, packaged, and labeled for the study by Sharp Labs. The study will follow standard dosing procedures for extended-release metformin. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.

    Also known as: Glumetza, Fortamet, Glucophage extended release (XR)

  • DrugPlacebo

    The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.

06

What researchers measure

Primary outcomes

  1. KOOS Pain Score

    To determine whether metformin leads to reduced pain as measured by the KOOS pain subscale compared to placebo between 12 and 24 months postoperatively. Knee Injury and Osteoarthritis Outcome Score (KOOS) is a questionnaire designed to assess short and long-term patient-relevant outcomes following knee injury. The KOOS pain subscale contains 9 items and is scored on a 0-100 scale, 100 being best.

    Time frame: Average of 12 and 24 months

  2. Modified MOAKS Cartilage Score

    To determine whether metformin leads to reduced structural degeneration at 24 months postoperatively compared to placebo. The MOAKS score (MRI Osteoarthritis Knee Score) is a semi-quantitative whole joint assessment of knee osteoarthritis with very good to excellent reliability used to score knee osteoarthritis. In MOAKS the knee is divided into 14 articular subregions for scoring articular cartilage and bone marrow lesions (BMLs) and in addition the subspinous region is added for BML scoring. For each region, the following features are assessed independently: 1. bone marrow lesions and cysts (score: 0-3, 3 worst) 2. articular cartilage loss (score: 0-3, 3 worst) 3. osteophytes (score: 0-3, 3 worst) 4. synovitis and effusion (score: 0-3, 3 worst) 5. meniscus extrusion and morphology (score: 0-3, 3 worst) 6. ligaments/tendon (0/1, 0=normal, 1=abnormal) 7. periarticular features (0/1, 0=absent, 1=present)

    Time frame: 24 months

Secondary outcomes

  1. KOOS Pain

    Assessed via questionnaire. Knee Injury and Osteoarthritis Outcome Score (KOOS) is a questionnaire designed to assess short and long-term patient-relevant outcomes following knee injury. The KOOS is self-administered and includes 42 items across 5 subscales: pain, symptoms, ADLs, sports/recreation, and quality of life. KOOS is scored on a 0-100 scale, 100 being best. The pain subscale contains 9 items.

    Time frame: baseline, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months

  2. KOOS Symptoms

    Assessed via questionnaire. Knee Injury and Osteoarthritis Outcome Score (KOOS) is a questionnaire designed to assess short and long-term patient-relevant outcomes following knee injury. The KOOS is self-administered and includes 42 items across 5 subscales: pain, symptoms, ADLs, sports/recreation, and quality of life. KOOS is scored on a 0-100 scale, 100 being best. The symptoms subscale contains 7 items.

    Time frame: baseline, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months

  3. KOOS Activities of Daily Living (ADL)

    Assessed via questionnaire. Knee Injury and Osteoarthritis Outcome Score (KOOS) is a questionnaire designed to assess short and long-term patient-relevant outcomes following knee injury. The KOOS is self-administered and includes 42 items across 5 subscales: pain, symptoms, activities of daily living (ADLs), sports/recreation, and quality of life. KOOS is scored on a 0-100 scale, 100 being best. The ADL subscale contains 17 items.

    Time frame: baseline, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months

  4. KOOS Sport and Recreation Function

    Assessed via questionnaire. Knee Injury and Osteoarthritis Outcome Score (KOOS) is a questionnaire designed to assess short and long-term patient-relevant outcomes following knee injury. The KOOS is self-administered and includes 42 items across 5 subscales: pain, symptoms, ADLs, sports/recreation, and quality of life. KOOS is scored on a 0-100 scale, 100 being best. The sports and recreation subscale contains five items.

    Time frame: baseline, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months

  5. KOOS Quality of Life

    Assessed via questionnaire. Knee Injury and Osteoarthritis Outcome Score (KOOS) is a questionnaire designed to assess short and long-term patient-relevant outcomes following knee injury. The KOOS is self-administered and includes 42 items across 5 subscales: pain, symptoms, ADLs, sports/recreation, and quality of life. KOOS is scored on a 0-100 scale, 100 being best. The quality of life subscale contains four items.

    Time frame: baseline, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months

  6. Marx Activity Rating Scale

    Assessed via questionnaire The Marx Scale consists of four questions concerning running, cutting, deceleration, and pivoting. The patient is asked to report on the frequency with which they performed the activity in their healthiest state within the past year. It is most often used in physically active adults aged 18-50 with knee problems.

    Time frame: baseline, 12 months, 24 months

  7. Work Productivity and Activity Impairment (WPAI)

    Assessed via questionnaire The Work Productivity and Activity Impairment (WPAI) questionnaire is a 6-item instrument to measure impairments in both paid work and unpaid work. It measures impairments in paid work and other activity because of health problems during the past seven days.

    Time frame: baseline, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months

  8. EuroQoL Score

    Assessed via questionnaire The 5-level EuroQol score (EQ-5D-5L) is a quality of life measure that includes two components: the EQ descriptive system (EQ-5D) and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The scores for the five dimensions can be combined into a 5-digit number that describes the patient's health state (5-25, 25 worst). The EQ VAS records the patient's self-rated health on a visual analogue scale (0-100, 100 best).

    Time frame: baseline, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months

  9. Tampa Scale of Kinesiophobia Score

    Assessed via questionnaire The Tampa Scale of Kinesiophobia (TSK) is a 17-item questionnaire with a 4-point Likert scale to assess one's fear of movement or reinjury. Two subscales make up the scale: 1. Avoiding physical exertion because of fear of reinjury or worsening of pain (Questions 1, 2, 7, 9, 10, 11, 12) 2. Somatic Focus - the idea that there are underlying, major medical issues involved (Questions 3, 4, 5, 6, 8) Individual item scores range from 1-4 (4 worst), with the negatively worded items (4, 8, 12, 16) having a reverse scoring (4-1, 1 worst). The 17 item TSK total scores range from 17 to 68 where the lowest 17 means no kinesiophobia, and the higher scores indicate an increasing degree of kinesiophobia. Scores above 37 are generally considered to indicate kinesiophobia.

    Time frame: baseline, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months

  10. MHI-5 Score

    Assessed via questionnaire The Mental Health Inventory-5 (MHI-5) is a brief, valid, and reliable international instrument for assessing mental health status in adults. The MHI-5 has 5 items and is scored on a scale from 0-100, where 100 indicates optimal mental health.

    Time frame: baseline, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months

  11. Joint Space Narrowing Over Time

    Joint space narrowing will be measured in mm and assessed via X-Ray and MRI. Greater joint space narrowing indicates more severe structural osteoarthritis.

    Time frame: baseline, 12 months, 24 months

  12. Cartilage composition assessed with T1rho, T2

    Assessed via compositional MRI with T1rho and T2 weighted sequences, which are being investigated for their usefulness in musculoskeletal imaging, particularly for examining cartilage.

    Time frame: baseline, 12 months, 24 months

  13. Severity of Synovitis on Contrast MRI

    Assessed via optional contrast MRI. Dynamic contrast enhanced MR images will be analyzed to quantify variables including maximum enhancement, number of enhanced voxels, and derived variables (e.g. maximum enhancement times number of enhanced voxels) for evaluating severity of synovitis.

    Time frame: baseline, 12 months

  14. Knee Range of Motion

    Assessed via physical examination with a goniometer

    Time frame: 12 and 24 months

  15. 3D Gait Biomechanics

    Walking gait will be evaluated using a motion capture system as participants walk at a self-selected speed

    Time frame: 12 and 24 months

  16. Isokinetic knee flexion/extension strength at 60º/sec

    Assessed using an isokinetic dynamometer

    Time frame: 12 and 24 months

  17. 10m Habitual Walking Speed

    The time to walk 10 m will be recorded

    Time frame: 12 and 24 months

  18. Single Leg Hop Test

    The maximum distance will be recorded

    Time frame: 12 and 24 months

07

Study locations

9 of 9 sites recruiting
  • Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
    • Gregory D Myer, PhD · Principal investigator
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
    Recruiting
    • Don D Anderson, PhD · Principal investigator
    • Brian R Wolf, MD · Principal investigator
  • University of Kentucky
    Lexington, Kentucky 40504, United States
    Recruiting
    • Austin V Stone, MD, PhD · Principal investigator
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Rachel Lovejoy · Contactrlovejoy@bwh.harvard.edu · 6177326934
    • Morgan H Jones, MD, MPH · Principal investigator
    • Cale A Jacobs, PhD · Principal investigator
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
    Recruiting
    • Elizabeth A Wellsandt, PT, PhD · Principal investigator
    • Yvonne Golightly, PT, PhD · Principal investigator
  • Hospital for Special Surgery
    New York, New York 10021, United States
    Recruiting
    • Scott A Rodeo, MD · Principal investigator
    • Miguel Otero, PhD · Principal investigator
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 25599, United States
    Recruiting
    • Joe M Hart, PhD · Principal investigator
    • Brian G Pietrosimone, PhD · Principal investigator
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Kurt Spindler, MD · Principal investigator
  • The Ohio State University
    Columbus, Ohio 43210, United States
    Recruiting
    • Laura C Schmitt, PT, PhD · Principal investigator
    • Robert A Magnussen, MD · Principal investigator
08

References and documents

Publications

  • Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4. Epub 2015 Jun 7. PubMed 26063472 ↗
  • Brown TD, Johnston RC, Saltzman CL, Marsh JL, Buckwalter JA. Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma. 2006 Nov-Dec;20(10):739-44. doi: 10.1097/01.bot.0000246468.80635.ef. PubMed 17106388 ↗
  • Thomas AC, Hubbard-Turner T, Wikstrom EA, Palmieri-Smith RM. Epidemiology of Posttraumatic Osteoarthritis. J Athl Train. 2017 Jun 2;52(6):491-496. doi: 10.4085/1062-6050-51.5.08. Epub 2016 May 4. PubMed 27145096 ↗
  • Brinlee AW, Dickenson SB, Hunter-Giordano A, Snyder-Mackler L. ACL Reconstruction Rehabilitation: Clinical Data, Biologic Healing, and Criterion-Based Milestones to Inform a Return-to-Sport Guideline. Sports Health. 2022 Sep-Oct;14(5):770-779. doi: 10.1177/19417381211056873. Epub 2021 Dec 13. PubMed 34903114 ↗
  • Lim YZ, Wang Y, Estee M, Abidi J, Udaya Kumar M, Hussain SM, Wluka AE, Little CB, Cicuttini FM. Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies. Osteoarthritis Cartilage. 2022 Nov;30(11):1434-1442. doi: 10.1016/j.joca.2022.05.005. Epub 2022 May 18. PubMed 35597372 ↗
  • Wang Y, Hussain SM, Wluka AE, Lim YZ, Abram F, Pelletier JP, Martel-Pelletier J, Cicuttini FM. Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative-a prospective cohort study. Arthritis Res Ther. 2019 May 24;21(1):127. doi: 10.1186/s13075-019-1915-x. PubMed 31126352 ↗
  • Adams D, Logerstedt DS, Hunter-Giordano A, Axe MJ, Snyder-Mackler L. Current concepts for anterior cruciate ligament reconstruction: a criterion-based rehabilitation progression. J Orthop Sports Phys Ther. 2012 Jul;42(7):601-14. doi: 10.2519/jospt.2012.3871. Epub 2012 Mar 8. PubMed 22402434 ↗
  • Jacobs CA, Jones MH, Collins JE, Waddell LM, Li X, Winalski CS, Pietrosimone B, Kraus VB, Otero M, Wellsandt E, Schmitt LC, Spindler KP, Anderson DD, Rodeo SA, Magnussen RA, Wolf BR, Hart JM, Stone AV, Conley CE, Golightly YM, Myer GD, Snyder-Mackler L, Lotz MK, Kim JS, McLeod MM, Huebner JL, Lisee C, Selzer F, Katz JN, Long K, Frier KC, Betensky DJ, Felson DT, Losina E; for PIKASO Team. The PIKASO trial (Preventing Injured Knees from Osteoarthritis: Severity Outcomes): Rationale and design features for a randomized controlled trial. Osteoarthr Cartil Open. 2024 Dec 23;7(1):100563. doi: 10.1016/j.ocarto.2024.100563. eCollection 2025 Mar. PubMed 39867299 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2029, 67 months after the start.

Of 43 non-industry phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's planned 67 months is above that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Dec 2028 → Dec 2029 and completion Dec 2029 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 23, 2023
StartActual
May 6, 2024
Primary completionEst.
Dec 2029was Dec 2028
CompletionEst.
Dec 2030was Dec 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2028→Dec 2029
Oct 15, 2026
Study completion
Dec 2029→Dec 2030
Oct 15, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39867299 ↗
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39867299 ↗
    Primary completion Dec 2028→Dec 2029
    Study completion Dec 2029→Dec 2030
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06096259
Collaborators
Arthritis Foundation
Responsible party
Morgan H. Jones, MD, MPH (Assistant Professor of Orthopedic Surgery, Brigham and Women's Hospital) — Principal investigator
First posted
Oct 23, 2023
Start date
May 6, 2024
Primary completion
Dec 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Faith Selzer, PhD
Contact
fselzer@bwh.harvard.edu
617-525-8617
Daniel J Betensky, AB
Contact
dbetensky@bwh.harvard.edu
6175259727
Morgan H Jones, MD, MPH
principal investigator · Brigham and Women's Hospital
Cale A Jacobs, PhD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion